Mount Sinai Innovation Partners

MSIP is the internal commercialization and venture-investment division of the Mount Sinai Health System, not a third-party limited partnership. It invests directly from the health system's balance sheet, which eliminates the fixed fund-life horizon that governs most venture firms and allows it to hold positions through extended clinical-regulatory timelines. The office's portfolio companies also gain access to Mount Sinai's hospital network for clinical validation — a de-risking mechanism unavailable to startups funded by generalist venture firms.

Erik Lium, MSIP's president, leads the office's investment decisions, supported by a team that evaluates faculty invention disclosures, market size, and patentability. The office determines whether a technology should be licensed to an existing company, spun out into a new venture with internal funding, or partnered directly with a pharmaceutical or med-tech corporate collaborator. Individual investment committee composition is not publicly detailed, but Mount Sinai's chief commercial innovation and legal officers typically participate in material allocation decisions.

Both. MSIP leads or participates in seed rounds for spinouts it incubates, often syndicating deals to external life-science and digital-health venture funds. In some cases, the external firm leads the round while MSIP contributes intellectual property, clinical-access rights, and follow-on equity. The office also structures corporate partnerships with pharmaceutical and medical-device companies that may include milestone payments and co-development rights alongside equity participation.

The office holds a mix of equity stakes in venture-backed spinouts, licensing royalties from technologies that are outlicensed to third parties, and revenue-sharing agreements tied to corporate research partnerships. When Mount Sinai faculty invent a new therapeutic, diagnostic, or digital-health platform, MSIP files patents through its in-house IP team and then determines whether commercialization should proceed via a royalty-bearing license to an existing company or a new equity-funded startup in which Mount Sinai retains a significant ownership position.

MSIP does not operate a traditional venture fund open to external LP commitments. Its investment capital comes from the Mount Sinai Health System's balance sheet and research-related income. However, the office regularly syndicates individual spinout investment rounds to external venture firms and corporate strategic partners, making co-investment access available on a deal-by-deal basis. Detailed information on syndication criteria or minimum co-investment amounts is not publicly disclosed.